evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

7 questions · 7 findings · 2 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 1 · 14.3%GRADE not reported 0 · 0%Very low 3 · 42.9%Low 2 · 28.6%Moderate 1 · 14.3%High 0 · 0%

Infliximab 5 mg/kg vs CT‐P13 biosimilar 5 mg/kg

Clinical response defined by reduction of CDAI score by ≥ 100 at week 6 · Patients with active Crohn's disease

Infliximab 5 mg/kg showed no clear difference in clinical response defined by reduction of CDAI score by ≥ 100 at… compared with CT‐P13 biosimilar 5 mg/kg (low certainty).

1 finding from 1 review

Infliximab 5 mg/kg vs infliximab 10 mg/kg

Clinical response defined as reduction of 50% in the number of draining fistula at ≥ 2 consecutive visits, at a median length of time of 12 weeks · Patients with active Crohn's disease

It is very uncertain whether infliximab 5 mg/kg changes clinical response defined as reduction of 50% in the number of… compared with infliximab 10 mg/kg (very low certainty).

1 finding from 1 review

Infliximab 5 mg/kg and purine analogues vs purine analogues

Clinical response as defined by the studies at week 26 · Patients with active Crohn's disease

Infliximab 5 mg/kg and purine analogues probably leads to higher clinical response as defined by the studies at week 26 compared with purine analogues alone (moderate certainty).

1 finding from 1 review